Johnson & Johnson
This article was originally published in The Tan Sheet
Executive Summary
McNeil Consumer fourth quarter worldwide growth of 19% was "primarily the result" of the buyout of Merck's equity stake in the European nonprescription pharmaceutical business, J&J reports. Inspired by strong performance from Splenda, McNeil is "continuing to look at models and new opportunities to broaden that whole nutritional area, so we've got a whole organization looking at it" reports J&J CEO William Weldon. "We do feel there's a big opportunity, especially with the needs of childhood obesity and other things that are out there today." J&J global fourth quarter sales increased 13.3% to $12.8 bil...